<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39356507</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>e2436874</StartPage><MedlinePgn>e2436874</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2436874</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2024.36874</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Neurologic post-COVID-19 condition (PCC), or long COVID, symptoms of fatigue and cognitive dysfunction continue to affect millions of people who have been infected with SARS-CoV-2. There currently are no effective evidence-based therapies available for treating neurologic PCC.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To assess the effects of lithium aspartate therapy on PCC fatigue and cognitive dysfunction.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">A randomized, double-blind, placebo-controlled trial (RCT) enrolling participants in a neurology clinic from November 28, 2022, to June 29, 2023, with 3 weeks of follow-up, was conducted. Subsequently, an open-label lithium dose-finding study with 6 weeks of follow-up was performed among the same participants enrolled in the RCT. Eligible individuals needed to report new, bothersome fatigue or cognitive dysfunction persisting for more than 4 weeks after a self-reported positive test for COVID-19, Fatigue Severity Scale-7 (FSS-7) or Brain Fog Severity Scale (BFSS) score of 28 or greater, Beck Depression Inventory-II score less than 24, and no history of a condition known to cause fatigue or cognitive dysfunction. All participants in the RCT were eligible for the dose-finding study, except for those who responded to the placebo. Intention-to-treat analysis was used.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Lithium aspartate, 10 to 15 mg/d, or identically appearing placebo for 3 weeks followed by open-label lithium aspartate, 10 to 15 mg/d, for 2 weeks. In the subsequent dose-finding study, open-label lithium aspartate dosages up to 45 mg/d for 6 weeks were given.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">Change in sum of FSS-7 and BFSS scores. The scores for each measure range from 7 to 49, with higher scores indicating more severe symptoms. Secondary outcomes included changes from baseline in the scores of additional questionnaires.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Fifty-two participants were enrolled (30 [58%] males; mean [SD] age, 58.54 [14.34] years) and 26 were randomized to treatment with lithium aspartate (10 females) and 26 to placebo (12 female). Two participants assigned to lithium aspartate were lost to follow-up and none withdrew. No adverse events were attributable to lithium therapy. There were no significant intergroup differences for the primary outcome (-3.6; 95% CI, -16.6 to 9.5; P&#x2009;=&#x2009;.59) or any secondary outcomes. Among 3 patients completing a subsequent dose-finding study, open-label lithium aspartate, 40 to 45 mg/d, was associated with numerically greater reductions in fatigue and cognitive dysfunction scores than 15 mg/d, particularly in 2 patients with serum lithium levels of 0.18 and 0.49 mEq/L compared with 1 patient with a level of 0.10 mEq/L.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this RCT, therapy with lithium aspartate, 10 to 15 mg/d, was ineffective for neurologic PCC fatigue and cognitive dysfunction. Another RCT is required to assess the potential benefits of higher lithium dosages for treating neurologic PCC.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT05618587 and NCT06108297.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guttuso</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Williamsville, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jingtao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Williamsville, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilding</LastName><ForeName>Gregory E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Williamsville, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05618587</AccessionNumber><AccessionNumber>NCT06108297</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Netw Open. 2024 Oct 1;7(10):e2444512. doi: 10.1001/jamanetworkopen.2024.44512</RefSource><PMID Version="1">39446333</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="Y">Fatigue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="Y">Aspartic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Guttuso reported being president of e3 Pharmaceuticals. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>2</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39356507</ArticleId><ArticleId IdType="pmc">PMC11447566</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.36874</ArticleId><ArticleId IdType="pii">2824334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention . Clinical overview of long COVID. July 12, 2024. Accessed April 14, 2024. https://www.cdc.gov/covid/hcp/clinical-overview/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
</Citation></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. ; RECOVER Consortium . Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934-1946. doi:10.1001/jama.2023.8823</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.8823</ArticleId><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosentino G, Todisco M, Hota N, et al. . Neuropathological findings from COVID-19 patients with neurological symptoms argue against a direct brain invasion of SARS-CoV-2: a critical systematic review. Eur J Neurol. 2021;28(11):3856-3865. doi:10.1111/ene.15045</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15045</ArticleId><ArticleId IdType="pmc">PMC8444743</ArticleId><ArticleId IdType="pubmed">34339563</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J, L&#xfc;tgehetmann M, Hagel C, et al. . Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19(11):919-929. doi:10.1016/S1474-4422(20)30308-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga J, Lepra M, Kish SJ, et al. . Neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms. JAMA Psychiatry. 2023;80(8):787-795. doi:10.1001/jamapsychiatry.2023.1321</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2023.1321</ArticleId><ArticleId IdType="pmc">PMC10233457</ArticleId><ArticleId IdType="pubmed">37256580</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser D, Golla SSV, Verfaillie SCJ, et al. . Long COVID is associated with extensive in-vivo neuroinflammation on [18F]DPA-714 PET. medRxiv. Preprint posted online June 4, 2022. doi:10.1101/2022.06.02.22275916</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.02.22275916</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42. doi:10.1186/s40035-020-00221-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-020-00221-2</ArticleId><ArticleId IdType="pmc">PMC7689983</ArticleId><ArticleId IdType="pubmed">33239064</ArticleId></ArticleIdList></Reference><Reference><Citation>Capone F, Collorone S, Cortese R, Di Lazzaro V, Moccia M. Fatigue in multiple sclerosis: the role of thalamus. Mult Scler. 2020;26(1):6-16. doi:10.1177/1352458519851247</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458519851247</ArticleId><ArticleId IdType="pubmed">31138052</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonheim MM, Hulst HE, Brandt RB, et al. . Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology. 2015;84(8):776-783. doi:10.1212/WNL.0000000000001285</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001285</ArticleId><ArticleId IdType="pubmed">25616483</ArticleId></ArticleIdList></Reference><Reference><Citation>Liljeholm M, O&#x2019;Doherty JP. Contributions of the striatum to learning, motivation, and performance: an associative account. Trends Cogn Sci. 2012;16(9):467-475. doi:10.1016/j.tics.2012.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2012.07.007</ArticleId><ArticleId IdType="pmc">PMC3449003</ArticleId><ArticleId IdType="pubmed">22890090</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttuso T Jr, Sirica D, Tosun D, et al. . Thalamic dorsomedial nucleus free water correlates with cognitive decline in Parkinson&#x2019;s disease. Mov Disord. 2022;37(3):490-501. doi:10.1002/mds.28886</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28886</ArticleId><ArticleId IdType="pmc">PMC8940677</ArticleId><ArticleId IdType="pubmed">34936139</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi Y, Yoshikawa E, Sekine Y, et al. . Microglial activation and dopamine terminal loss in early Parkinson&#x2019;s disease. Ann Neurol. 2005;57(2):168-175. doi:10.1002/ana.20338</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20338</ArticleId><ArticleId IdType="pubmed">15668962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreisl WC, Lyoo CH, McGwier M, et al. ; Biomarkers Consortium PET Radioligand Project Team . In vivo radioligand binding to translocator protein correlates with severity of Alzheimer&#x2019;s disease. Brain. 2013;136(Pt 7):2228-2238. doi:10.1093/brain/awt145</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt145</ArticleId><ArticleId IdType="pmc">PMC3692038</ArticleId><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>Suridjan I, Pollock BG, Verhoeff NP, et al. . In-vivo imaging of grey and white matter neuroinflammation in Alzheimer&#x2019;s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. Mol Psychiatry. 2015;20(12):1579-1587. doi:10.1038/mp.2015.1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.1</ArticleId><ArticleId IdType="pmc">PMC8026116</ArticleId><ArticleId IdType="pubmed">25707397</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutin H, Murray K, Pradillo J, et al. . 18F-GE-180: a novel TSPO radiotracer compared to 11C-R-PK11195 in a preclinical model of stroke. Eur J Nucl Med Mol Imaging. 2015;42(3):503-511. doi:10.1007/s00259-014-2939-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-014-2939-8</ArticleId><ArticleId IdType="pubmed">25351507</ArticleId></ArticleIdList></Reference><Reference><Citation>Dell&#x2019;Osso L, Del Grande C, Gesi C, Carmassi C, Musetti L. A new look at an old drug: neuroprotective effects and therapeutic potentials of lithium salts. Neuropsychiatr Dis Treat. 2016;12:1687-1703. doi:10.2147/NDT.S106479</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S106479</ArticleId><ArticleId IdType="pmc">PMC4946830</ArticleId><ArticleId IdType="pubmed">27468233</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Zhang X, Dai X, et al. . Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway. J Neuroinflammation. 2014;11:140. doi:10.1186/s12974-014-0140-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-014-0140-4</ArticleId><ArticleId IdType="pmc">PMC4149204</ArticleId><ArticleId IdType="pubmed">25115727</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Li Q, Du X, et al. . Lithium-mediated long-term neuroprotection in neonatal rat hypoxia-ischemia is associated with antiinflammatory effects and enhanced proliferation and survival of neural stem/progenitor cells. J Cereb Blood Flow Metab. 2011;31(10):2106-2115. doi:10.1038/jcbfm.2011.75</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2011.75</ArticleId><ArticleId IdType="pmc">PMC3208156</ArticleId><ArticleId IdType="pubmed">21587270</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Zhang X, Dong H, Zhang S, Sun J, Qian Y. Lithium ameliorates LPS-induced astrocytes activation partly via inhibition of toll-like receptor 4 expression. Cell Physiol Biochem. 2016;38(2):714-725. doi:10.1159/000443028</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000443028</ArticleId><ArticleId IdType="pubmed">26870942</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieu CA, Dewey CM, Chinta SJ, et al. . Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model. Brain Res. 2014;1591:111-117. doi:10.1016/j.brainres.2014.10.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2014.10.032</ArticleId><ArticleId IdType="pmc">PMC4254598</ArticleId><ArticleId IdType="pubmed">25452026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Wang Z, Tchantchou F, Chiu CT, Zhang Y, Chuang DM. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. J Neurotrauma. 2012;29(2):362-374. doi:10.1089/neu.2011.1942</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2011.1942</ArticleId><ArticleId IdType="pmc">PMC3261788</ArticleId><ArticleId IdType="pubmed">21895523</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttuso T Jr, Shepherd R, Frick L, et al. . Lithium&#x2019;s effects on therapeutic targets and MRI biomarkers in Parkinson&#x2019;s disease: a pilot clinical trial. IBRO Neurosci Rep. 2023;14:429-434. doi:10.1016/j.ibneur.2023.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ibneur.2023.05.001</ArticleId><ArticleId IdType="pmc">PMC10196787</ArticleId><ArticleId IdType="pubmed">37215748</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttuso T Jr, Russak E, De Blanco MT, Ramanathan M. Could high lithium levels in tobacco contribute to reduced risk of Parkinson&#x2019;s disease in smokers? J Neurol Sci. 2019;397:179-180. doi:10.1016/j.jns.2019.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.01.009</ArticleId><ArticleId IdType="pubmed">30641248</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerdal A, Johansson S, Kottorp A, von Koch L. Psychometric properties of the Fatigue Severity Scale: Rasch analyses of responses in a Norwegian and a Swedish MS cohort. Mult Scler. 2010;16(6):733-741. doi:10.1177/1352458510370792</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458510370792</ArticleId><ArticleId IdType="pubmed">20558503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerdal A, Kottorp A. Psychometric properties of the Fatigue Severity Scale-Rasch analyses of individual responses in a Norwegian stroke cohort. Int J Nurs Stud. 2011;48(10):1258-1265. doi:10.1016/j.ijnurstu.2011.02.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijnurstu.2011.02.019</ArticleId><ArticleId IdType="pubmed">21414620</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan P, Shedden-Mora MC, L&#xf6;we B. Psychometric analysis of the Generalized Anxiety Disorder scale (GAD-7) in primary care using modern item response theory. PLoS One. 2017;12(8):e0182162. doi:10.1371/journal.pone.0182162</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182162</ArticleId><ArticleId IdType="pmc">PMC5542568</ArticleId><ArticleId IdType="pubmed">28771530</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware J Jr, Kosinski M, Keller SDA. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233. doi:10.1097/00005650-199603000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199603000-00003</ArticleId><ArticleId IdType="pubmed">8628042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebrahimi N, Maltepe C, Bournissen FG, Koren G. Nausea and vomiting of pregnancy: using the 24-hour Pregnancy-Unique Quantification of Emesis (PUQE-24) scale. J Obstet Gynaecol Can. 2009;31(9):803-807. doi:10.1016/S1701-2163(16)34298-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1701-2163(16)34298-0</ArticleId><ArticleId IdType="pubmed">19941704</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastien CH, Valli&#xe8;res A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001;2(4):297-307. doi:10.1016/S1389-9457(00)00065-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-9457(00)00065-4</ArticleId><ArticleId IdType="pubmed">11438246</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeger J. Digit Symbol Substitution Test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol. 2018;38(5):513-519. doi:10.1097/JCP.0000000000000941</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCP.0000000000000941</ArticleId><ArticleId IdType="pmc">PMC6291255</ArticleId><ArticleId IdType="pubmed">30124583</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al. . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. doi:10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Columbano A, Ledda GM, Rao PM, Rajalakshmi S, Sarma DS. Dietary orotic acid, a new selective growth stimulus for carcinogen altered hepatocytes in rat. Cancer Lett. 1982;16(2):191-196. doi:10.1016/0304-3835(82)90060-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3835(82)90060-X</ArticleId><ArticleId IdType="pubmed">6127157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokkinakis DM, Albores-Saavedra J. Orotic acid enhancement of preneoplastic and neoplastic lesions induced in the pancreas and liver of hamsters by N-nitroso(2-hydroxypropyl) (2-oxopropyl)amine. Cancer Res. 1994;54(20):5324-5332.</Citation><ArticleIdList><ArticleId IdType="pubmed">7923160</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokkinakis DM, Scarpelli DG, Oyasu R. Enhancement of N-nitroso(2-hydroxypropyl)(2-oxopropyl)amine-induced tumorigenesis in Sprague-Dawley rats by orotic acid. Carcinogenesis. 1991;12(2):181-186. doi:10.1093/carcin/12.2.181</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/12.2.181</ArticleId><ArticleId IdType="pubmed">1995183</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407-415. doi:10.1016/0197-2456(89)90005-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(89)90005-6</ArticleId><ArticleId IdType="pubmed">2691207</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi GS, Gershon S, Outhred T. Lithiumeter: version 2.0. Bipolar Disord. 2016;18(8):631-641. doi:10.1111/bdi.12455</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bdi.12455</ArticleId><ArticleId IdType="pubmed">28063207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney S, McFadyen DA, Wood DL, Moffat DF, Paul PL. Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Mult Scler Relat Disord. 2019;35:158-163. doi:10.1016/j.msard.2019.07.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2019.07.028</ArticleId><ArticleId IdType="pubmed">31400557</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumiyoshi T, Uchida H, Watanabe K, et al. . Validation and functional relevance of the short form of the Perceived Deficits Questionnaire for Depression for Japanese patients with major depressive disorder. Neuropsychiatr Dis Treat. 2022;18:2507-2517. doi:10.2147/NDT.S381647</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S381647</ArticleId><ArticleId IdType="pmc">PMC9639589</ArticleId><ArticleId IdType="pubmed">36353465</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison SA, Baum SJ, Gunn NT, et al. . Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease. Am J Gastroenterol. 2021;116(12):2399-2409. doi:10.14309/ajg.0000000000001375</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001375</ArticleId><ArticleId IdType="pmc">PMC8631161</ArticleId><ArticleId IdType="pubmed">34382947</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnigan LEM, Cassar MP, Koziel MJ, et al. . Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study. EClinicalMedicine. 2023;59:101946. doi:10.1016/j.eclinm.2023.101946</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101946</ArticleId><ArticleId IdType="pmc">PMC10102537</ArticleId><ArticleId IdType="pubmed">37223439</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS, Phan L, Kwan ATH, et al. . Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. Brain. 2024;147(3):849-857. doi:10.1093/brain/awad377</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awad377</ArticleId><ArticleId IdType="pubmed">37936330</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak O, Shenton ME, Westin CF. Estimation of extracellular volume from regularized multi-shell diffusion MRI. Med Image Comput Comput Assist Interv. 2012;15(Pt 2):305-312. doi:10.1007/978-3-642-33418-4_38</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-642-33418-4_38</ArticleId><ArticleId IdType="pmc">PMC4039075</ArticleId><ArticleId IdType="pubmed">23286062</ArticleId></ArticleIdList></Reference><Reference><Citation>Febo M, Perez PD, Ceballos-Diaz C, et al. . Diffusion magnetic resonance imaging-derived free water detects neurodegenerative pattern induced by interferon-&#x3b3;. Brain Struct Funct. 2020;225(1):427-439. doi:10.1007/s00429-019-02017-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-019-02017-1</ArticleId><ArticleId IdType="pmc">PMC7003714</ArticleId><ArticleId IdType="pubmed">31894407</ArticleId></ArticleIdList></Reference><Reference><Citation>Burciu RG, Ofori E, Archer DB, et al. . Progression marker of Parkinson&#x2019;s disease: a 4-year multi-site imaging study. Brain. 2017;140(8):2183-2192. doi:10.1093/brain/awx146</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx146</ArticleId><ArticleId IdType="pmc">PMC6057495</ArticleId><ArticleId IdType="pubmed">28899020</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, Diniz BS, Radanovic M, Santos FS, Talib LL, Gattaz WF. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. Br J Psychiatry. 2011;198(5):351-356. doi:10.1192/bjp.bp.110.080044</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.110.080044</ArticleId><ArticleId IdType="pubmed">21525519</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene C, Connolly R, Brennan D, et al. . Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024;27(3):421-432. doi:10.1038/s41593-024-01576-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-024-01576-9</ArticleId><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Boito D, Eklund A, Tisell A, Levi R, &#xd6;zarslan E, Blystad I. MRI with generalized diffusion encoding reveals damaged white matter in patients previously hospitalized for COVID-19 and with persisting symptoms at follow-up. Brain Commun. 2023;5(6):fcad284. doi:10.1093/braincomms/fcad284</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcad284</ArticleId><ArticleId IdType="pmc">PMC10638510</ArticleId><ArticleId IdType="pubmed">37953843</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolini M, Palladini M, Mazza MG, et al. . Brain correlates of subjective cognitive complaints in COVID-19 survivors: a multimodal magnetic resonance imaging study. Eur Neuropsychopharmacol. 2023;68:1-10. doi:10.1016/j.euroneuro.2022.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2022.12.002</ArticleId><ArticleId IdType="pmc">PMC9742225</ArticleId><ArticleId IdType="pubmed">36640728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofori E, DeKosky ST, Febo M, et al. ; Alzheimer&#x2019;s Disease Neuroimaging Initiative . Free-water imaging of the hippocampus is a sensitive marker of Alzheimer&#x2019;s disease. Neuroimage Clin. 2019;24:101985. doi:10.1016/j.nicl.2019.101985</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.101985</ArticleId><ArticleId IdType="pmc">PMC6722298</ArticleId><ArticleId IdType="pubmed">31470214</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu WT, Wang WE, Zaborszky L, et al. . Association of cognitive impairment with free water in the nucleus basalis of Meynert and locus coeruleus to transentorhinal cortex tract. Neurology. 2022;98(7):e700-e710. doi:10.1212/WNL.0000000000013206</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000013206</ArticleId><ArticleId IdType="pmc">PMC8865892</ArticleId><ArticleId IdType="pubmed">34906980</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>